Clinical trials: Septicemic Shock
Severe Sepsis and Septic Shock
Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock
This is the statistical analysis plan for an individual patient data meta-analysis (IPDMA) of three EGDT clinical trials.
- Trial name
- NCT02030158
- Volunteers
- 4,210 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Sepsis, Severe Sepsis
RCT of Sepsis Machine Learning Algorithm
The focus of this study will be to conduct a prospective, multi-center randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a machine-learning…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03882476
- Testing
- InSight
- Volunteers
- healthy volunteers welcome
- Sponsor
- Dascena
Septic Shock
Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock
Use Mannose Binding Lectin (MBL) as a biomarker to measure levels of Pathogen- Associated Molecular Patterns (PAMP) during septic shock. This will allow evaluating interest of this biomarker to monitor and manage a septic shock.
- Trial name
- Fc-MBL/PAMPs (NCT03457038)
- Testing
- Blood Test
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Toulouse
Sepsis, Septic Shock
Specific miRNAs in Sepsis and Nephrotoxic Antibiotic Treatment
Critically ill patients are prone to develop acute kidney injury due to sepsis itself and by administration of potentially nephrotoxic antibiotic treatment (vancomycin or gentamicin).
- Conditions
- Sepsis, Septic Shock, Acute Kidney Injury
- Trial name
- NCT04991376
- Testing
- Blood-specific miRNA levels
- Where
- Czechia
- Volunteers
- 53 people
- Sponsor
- University Hospital Ostrava
Septic Shock
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
The purpose of this trial is to investigate the potential of FE 202158 as a treatment which can stabilize blood pressure for treatment of patients in early septic shock.
- Trial name
- NCT01612676
- Testing
- FE 202158
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 31 people
- Sponsor
- Ferring Pharmaceuticals
Severe Sepsis, Persistent Hypotension
Epidemiology of Septic Shock in Medical or Polyvalent ICU in the North-East Region of France
The epidemiology of this study aims and outcome of patients with septic shock in the intensive care unit (or versatile) of the North-East region in france as well as the modalities of care.
- Trial name
- NCT01903746
- Volunteers
- 1,495 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Sepsis, Septic Shock
Administration of Human Protein C Concentrates in Patients With Sepsis and Septic Shock.
The purpose of this study is to investigate the effects on systemic hemodynamics, microcirculation and organ function of human Protein C concentrate in patients with sepsis and septic shock.
- Trial name
- NCT01411670
- Testing
- Human protein C concentrate, Activated protein C
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University of Roma La Sapienza
Septic Shock
Effect of Simulation Application in Septic Shock Management
This research will be conducted to determine the effect of the Tag Team Patient Safety Simulation application applied to second-year students of a university's Nursing Department on their knowledge level, patient safety attitudes…
- Trial name
- NCT07032779
- Testing
- simulation
- Where
- Turkey (Türkiye)
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Amasya University
Septic Shock
Modulation of Endothelial Dysfonction Using Vitamin C in Septic Shock Patients
Compare the microcirculatory reactivity before and after a 30-minute intravenous infusion of 40 mg/kg vitamin C and evaluate intra-individual variation of hemodynamic parameters between T0 and T1.
- Trial name
- MYTHICCS (NCT04778605)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Septic Shock, Sepsis
Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)
Sepsis is a common syndrome resulting from a dysregulated response to infection. The timing of antibiotic initiation is an important determinant of outcomes for patients presenting to the emergency department with sepsis.
- Trial name
- NCT03226366
- Testing
- Immediate evaluation by multidisciplinary team
- Where
- 4 sites in United States
- Volunteers
- 3,230 people
- Sponsor
- Intermountain Health Care, Inc.
Septic Shock, Endotoxemia
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge…
- Trial name
- EUPHRATES (NCT01046669)
- Testing
- TORAYMYXIN PMX-20R (PMX cartridge), Standard medical care for septic shock
- Where
- 40 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- Spectral Diagnostics (US) Inc.
Sepsis, Septic Shock
Immune Function Monitoring and Immunotherapy in Sepsis
At present, the clinical studies of various anti-inflammatory drugs and immune-enhancing drugs show that immunotherapy will bring new hope for the treatment of sepsis.
- Trial name
- IMITS (NCT04903405)
- Testing
- No intervention
- Volunteers
- 5,000 people
- Sponsor
- Sun Yat-sen University
Septic Shock
Treatment of Severe Infections With Mesenchymal Stem Cells
The main purpose at the early phase of septic shock on the evolution of organ failure judged by the SOFA (Sepsis Organ Failure Assessment score) score on Day 7 (or the day of death or the day of discharge from the intensive care…
- Trial name
- CHOCMSC (NCT02883803)
- Testing
- Injection of mesenchymal stem cells, Injection of albumin alone
- Where
- 4 sites in France
- Volunteers
- 66 people
- Sponsor
- Central Hospital, Nancy, France
the Coagulolytic Balance, the Mortality Rate
Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock
Septic shock is a clinical syndrome occurring in 10 to 20% of patients admitted in ICV. Mortality associated to septic shock varies from 30 to 50%.
- Conditions
- the Coagulolytic Balance, the Mortality Rate, the Performance Used to Evaluate the Principal Objective Are Technical Performances, Sensibility and Specificity of the Tests
- Trial name
- NCT02062970
- Testing
- blood draw
- Where
- France
- Volunteers
- 230 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Sepsis, Myocardial Injury
COronary Microcirculation and Troponin Elevation in Septic Shock
Plasma cardiac troponin (cTn) elevation is an indicator of increased mortality in patients with sepsis yet the underlying cause of troponin elevation in sepsis is not known.
- Conditions
- Sepsis, Myocardial Injury, Coronary Microvascular Dysfunction, Endothelial Dysfunction
- Trial name
- COMTESS (NCT06294730)
- Where
- Sweden
- Volunteers
- 62 people
- Sponsor
- Karolinska Institutet
Sepsis
Correlation Between PTP1B Expression and Organ Failure During Sepsis
Despite major advances in the treatment and understanding of the pathophysiological mechanisms, mortality of severe sepsis remains high, ranging from 25 to 50%.
- Trial name
- SEPP1B (NCT02295514)
- Testing
- PTP1B dosage
- Where
- France
- Volunteers
- 54 people
- Sponsor
- University Hospital, Rouen
Sepsis, Septic Shock
Nasal and Gut Microbiota Combined Clinical Events Predicts the Prognosis of Septic Patients
In this prospective, multicentered , diagnostic trial, nasal and fecal specimens will collected from patients with sepsis in two critical care units(ICU) at the enrollment day ,the third, seventh, and fourteen days after…
- Trial name
- NCT05143736
- Testing
- gut and nasal microbiota detection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhujiang Hospital
Shock, Septic
Tryptophan, Serotonin and Kynurenine in Septic Shock
Septic shock is a major cause of mortality and morbidity worldwide. Serotonin (5-HT) is released by activated platelets into the circulation, and is mediator of endothelial dysfunction.
- Trial name
- TSK (NCT00684736)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Versailles Hospital
Sepsis
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
The purpose of this placebo-controlled study is to determine if drotrecogin alfa (activated) treatment provides significant mortality reduction improvement in patients with septic shock compared with placebo treatment in patients…
- Trial name
- NCT00604214
- Testing
- Drotrecogin alfa (activated)
- Where
- 150 sites in United States, Australia and 16 more
- Volunteers
- 1,696 people
- Sponsor
- Eli Lilly and Company
Septic Shock, Shock
Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock
Norepinephrine is a catecholamine that is the first-line vasopressor for septic shock. The addition of non-catecholamine vasopressors, including vasopressin and angiotensin-II may be used in adults with septic shock that have…
- Conditions
- Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
- Trial name
- NCT06122987
- Testing
- Angiotensin II and hydrocortisone sodium succinate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Kingman Regional Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.